Crispr Theraptc (NASDAQ:CRSP) CEO Rodger Novak sold 75,795 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $20.25, for a total transaction of $1,534,848.75. Following the transaction, the chief executive officer now owns 1,232,697 shares in the company, valued at $24,962,114.25. The sale was disclosed in a filing with the SEC, which is available through this link.

Rodger Novak also recently made the following trade(s):

  • On Thursday, June 22nd, Rodger Novak sold 10,825 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.37, for a total transaction of $166,380.25.
  • On Wednesday, June 21st, Rodger Novak sold 30,222 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.01, for a total transaction of $453,632.22.
  • On Friday, June 9th, Rodger Novak sold 5,303 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.02, for a total transaction of $79,651.06.

Shares of Crispr Theraptc (CRSP) traded up 0.716% on Thursday, reaching $20.808. 187,494 shares of the company’s stock traded hands. The firm’s 50 day moving average is $17.74 and its 200 day moving average is $17.59. The firm’s market capitalization is $844.62 million. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00.

Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.06. The firm had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company’s revenue was up 350.0% compared to the same quarter last year. Analysts expect that Crispr Theraptc will post ($2.43) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/crispr-theraptc-crsp-ceo-rodger-novak-sells-75795-shares/1534625.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares in the last quarter. IHT Wealth Management LLC purchased a new position in shares of Crispr Theraptc during the first quarter worth $110,000. Wells Fargo & Company MN boosted its position in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new position in shares of Crispr Theraptc during the second quarter worth $206,000. Finally, Monashee Investment Management LLC boosted its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 23.90% of the company’s stock.

Several research analysts have issued reports on the stock. Cann assumed coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating on the stock. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. SunTrust Banks, Inc. assumed coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 target price on the stock. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Crispr Theraptc has an average rating of “Buy” and an average price target of $21.92.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.